[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Matutes E: Adult T-cell leukaemia/lymphoma. J Clin Pathol; 2007 Dec;60(12):1373-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukaemia/lymphoma.
  • Adult T-cell leukaemia/lymphoma (ATLL) is a mature T-cell neoplasm of post-thymic lymphocytes aetiologically linked to the human T-cell lymphotropic virus, HTLV-I, and with a distinct geographical distribution.
  • According to the disease manifestations, various forms which differ in clinical course and prognosis have been recognised: acute, chronic, smouldering and lymphoma.
  • The diagnosis should be based on a constellation of clinical features and laboratory investigations.
  • The latter comprise: lymphocyte morphology, immunophenotype, histology of the tissues affected in the pure lymphoma forms and serology or DNA analysis for HTLV-I.
  • The differential diagnosis of ATLL includes other mature T-cell neoplasms such as T-cell prolymphocytic leukaemia (T-PLL), Sézary syndrome (SS), peripheral T-cell lymphomas and occasionally healthy carriers of the virus or Hodgkin disease.
  • The clinical course is aggressive with a median survival of less than 12 months in the acute and lymphoma forms.
  • Despite major advances in understanding the pathogenesis of the disease, management of these patients remains a challenge for clinicians as they do not respond or achieve only transient responses to therapies used in high-grade lymphomas.
  • The use of antiretroviral agents such as zidovudine in combination with interferon-alpha, with or without concomitant chemotherapy, has shown activity in this disease with improvement in survival and response rate.
  • Consolidation with high dose therapy and autologous or allogeneic stem-cell transplantation should be considered in young patients.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Biomarkers, Tumor / blood. Diagnosis, Differential. Drug Therapy, Combination. Humans. Immunophenotyping. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Oct 1;56(7):1688-90 [2992744.001]
  • [Cites] Int J Cancer. 1985 Jan 15;35(1):65-72 [2578441.001]
  • [Cites] Lancet. 1987 Jul 11;2(8550):94-5 [2885585.001]
  • [Cites] Blood. 1987 Nov;70(5):1554-64 [2889485.001]
  • [Cites] Blood. 1988 Apr;71(4):1027-32 [2895676.001]
  • [Cites] Lancet. 1990 Oct 20;336(8721):987-90 [1977015.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):76-7 [1670727.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1622-8 [2001551.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):213-6 [7904671.001]
  • [Cites] Leukemia. 1994 Nov;8(11):1834-7 [7967729.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Leukemia. 1995 Apr;9(4):594-7 [7723390.001]
  • [Cites] Leukemia. 1995 Apr;9(4):598-604 [7723391.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):615-9 [7734362.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Leuk Lymphoma. 1995 May;17(5-6):459-64 [7549838.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):703-11 [9674744.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):511-5 [16098064.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3380-2 [16076875.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):103-5 [15979704.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):637-40 [10609805.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):41-4 [16247419.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1392-6 [18042695.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):779-84 [11380470.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Am J Hematol. 2004 Jun;76(2):187-9 [15164389.001]
  • [Cites] Leuk Res. 1985;9(11):1353-9 [2867255.001]
  • (PMID = 18042693.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 42
  • [Other-IDs] NLM/ PMC2095573
  •  go-up   go-down


2. Skoda-Smith S, Douglas VK, Mehta P, Graham-Pole J, Wingard JR: Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab. Bone Marrow Transplant; 2001 Feb;27(3):329-32
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab.
  • Management of monoclonal lymphoproliferative disease following stem cell transplantation is difficult and previous attempts to eradicate tumor using chemotherapy or radiation therapy alone have not been successful.
  • We report successful early eradication of an EBV negative, B cell non-Hodgkin's lymphoma in a child who received a T cell-depleted, maternal haploidentical bone marrow transplant for severe combined immunodeficiency disease.
  • Our treatment strategy involved combining conventional induction chemotherapy with re-transplantation using the paternal donor as a source of peripheral blood stem cells, followed by treatment with anti-CD 20 monoclonal antibody (Rituximab).
  • This strategy exploits the potential graft-versus-tumor activity of the mature T cells in the graft, while providing a source of stem cells to confer long-term immune function.
  • The administration of Rituximab in the early post-transplant course may provide additional anti-tumor activity without affecting the new stem cell compartment.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Haplotypes / immunology. Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoproliferative Disorders / therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Disease-Free Survival. Humans. Lymphoma, B-Cell / etiology. Lymphoma, B-Cell / therapy. Major Histocompatibility Complex / genetics. Major Histocompatibility Complex / immunology. Male. Remission Induction. Rituximab. Severe Combined Immunodeficiency / complications. Severe Combined Immunodeficiency / therapy

  • Genetic Alliance. consumer health - Post-transplant lymphoproliferative disease.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11277182.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


3. Shapiro M, Wasik MA, Junkins-Hopkins JM, Rook AH, Vittorio CC, Itakura H, Frankel MC, Georgala S, Schuster SJ: Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. Am J Hematol; 2003 Sep;74(1):46-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen.
  • Although its cell of origin is still controversial, the blastic NK-cell leukemia/lymphoma clearly represents a distinct type of hematopoietic neoplasm that is particularly clinically aggressive when it occurs in elderly patients as a disseminated, multi-organ disease.
  • Consistently effective treatments have not been developed for this malignancy.
  • The present report describes two elderly patients with widespread blastic NK-cell leukemia/lymphoma involving the skin, bone marrow, peripheral blood, lymph nodes, and viscera.
  • In both cases the malignant cells were CD56+, CD2+, and terminal deoxynucleotidyl transferase (TdT) positive with no detectable T-cell receptor (TCR) gamma chain gene rearrangement.
  • The above findings support the precursor NK-cell, rather than mature NK- or non-NK-cell, origin of the malignant cells.
  • It is noteworthy that the two patients achieved complete responses to treatment with hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) alternating with high-dose methotrexate/cytarabine, a regimen currently utilized in acute lymphoblastic leukemia and high-grade lymphoma.
  • The complete remission (CR) was sustained for 24 months in one patient who received four cycles (eight courses) of the treatment.
  • If similar results are obtained with future patients, a randomized study comparing the hyper-CVAD regimen to other therapeutic strategies may be warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Killer Cells, Natural / pathology. Leukemia / drug therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12949889.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA89194
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; CVAD protocol
  •  go-up   go-down


Advertisement
4. Zhang X, Inukai T, Hirose K, Akahane K, Nemoto A, Takahashi K, Sato H, Kagami K, Goi K, Sugita K, Nakazawa S: Induction of impaired membrane phospholipid asymmetry in mature erythrocytes after chemotherapy. Int J Hematol; 2005 Aug;82(2):132-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of impaired membrane phospholipid asymmetry in mature erythrocytes after chemotherapy.
  • Senescent erythrocytes undergo a loss of phospholipid asymmetry in the plasma membrane and are removed from the circulation by phagocytosis.To examine the loss of phospholipid asymmetry in mature erythrocytes after chemotherapy, we monitored phosphatidylserine (PS)-exposing erythrocytes by using flow cytometry to detect annexin V-bound erythrocytes in the circulation of acute lymphoblastic leukemia patients after consolidation chemotherapy.
  • Both the percentage and the absolute number of annexin V-positive erythrocytes gradually increased immediately after chemotherapy.
  • This result paralleled the change in the serum levels of bilirubin, suggesting a direct induction of PS-externalization in mature erythrocytes and a subsequent increase in erythrocyte clearance by splenic macrophages.
  • The PS-exposing erythrocyte counts showed negative correlations to platelet and reticulocyte counts, which reflect the hematopoietic potential in the bone marrow.
  • This result suggests that bone marrow suppression could be responsible for the enlarged senescent population in the circulation.
  • Moreover, PS-exposing erythrocytes in the circulation remained at relatively high levels even after the serum level of bilirubin normalized, indicating that the decreased clearance of senescent erythrocytes as a result of impaired phagocytosis following bone marrow suppression might also be involved in the increase in PS-exposing erythrocytes in the circulation late after chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Erythrocyte Membrane / metabolism. Phospholipids / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Annexin A5 / metabolism. Bone Marrow / metabolism. Bone Marrow / pathology. Cell Aging / drug effects. Erythropoiesis / drug effects. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1982 Jun;139(2):321-8 [6953013.001]
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1143-56 [11753563.001]
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1197-206 [11753567.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3077-81 [9501218.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1683-92 [10477693.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1121-32 [9028933.001]
  • [Cites] J Clin Invest. 1985 Jun;75(6):1965-72 [4008648.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1873-80 [8781447.001]
  • [Cites] J Biol Chem. 1994 Jan 28;269(4):2399-404 [8300565.001]
  • [Cites] J Immunol. 1997 Apr 15;158(8):3690-7 [9103432.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1179-87 [8562945.001]
  • [Cites] J Cell Sci. 1998 Sep;111 ( Pt 18):2707-15 [9718364.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(10):3311-5 [3458184.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2295-306 [11187921.001]
  • (PMID = 16146845.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antimetabolites, Antineoplastic; 0 / Phospholipids; 04079A1RDZ / Cytarabine
  •  go-up   go-down


5. Wuchter C, Ruppert V, Schrappe M, Dörken B, Ludwig WD, Karawajew L: In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood; 2002 Jun 1;99(11):4109-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia.
  • Within childhood T-cell acute lymphoblastic leukemia (T-ALL), patients with a cortical (CD1a(+)) immunophenotype have been identified as a subgroup with favorable outcome in the acute lymphoblastic leukemia-Berlin-Frankfurt-Münster (ALL-BFM), Cooperative study group for childhood acute lymphoblastic leukemia (COALL) and Pediatric Oncology Group studies.
  • We investigated in leukemic samples of children with T-ALL (n = 81) whether the different in vivo therapy response could be linked to differential in vitro susceptibility to apoptotic cell death.
  • When compared to cortical T-ALL, mature (CD1a(-), surface CD3(+)) T-ALL were significantly more resistant to doxorubicin, and immature, pro-/pre-T-ALL were more resistant to both drugs (P <.05).
  • Apoptosis-related parameters (Bax, Bcl-2, CD95, and CD95-induced apoptosis) did not account for differential susceptibility to drug-induced apoptosis.
  • Analysis of clinical data showed that in vitro susceptibility to dexamethasone (but not to doxorubicin) closely correlated with early in vivo therapy response characterized by percentages of blast cells in bone marrow on day 15 (r(s) = -0.46, P =.001).
  • Taken together, the in vitro assessment of drug-induced apoptosis revealed maturation-dependent differences within childhood T-ALL.
  • The enhanced sensitivity to both drugs in cortical T-ALL might account for the better in vivo treatment response of this prognostically favorable T-ALL subgroup.
  • [MeSH-major] Antigens, CD / analysis. Apoptosis / drug effects. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Interleukin-7 / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antigens, CD1 / analysis. Antigens, CD2 / analysis. Antigens, CD34 / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Child. Drug Resistance, Neoplasm. Humans. Immunophenotyping. Neoplasm Staging. Sialic Acid Binding Ig-like Lectin 3. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12010814.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD1; 0 / Antigens, CD2; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD1a antigen; 0 / CD33 protein, human; 0 / Interleukin-7; 0 / Sialic Acid Binding Ig-like Lectin 3; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin
  •  go-up   go-down


6. Lund T, Søe K, Abildgaard N, Garnero P, Pedersen PT, Ormstrup T, Delaissé JM, Plesner T: First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol; 2010 Oct;85(4):290-9
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
  • OBJECTIVES: The aim of the study was to investigate the effect of bortezomib on osteoblast proliferation and differentiation, as well as on bone matrix deposition for the first time in bisphosphonate-naïve, previously untreated patients with myeloma.
  • METHODS: Twenty newly diagnosed patients received four cycles of bortezomib treatment, initially as monotherapy and then combined with a glucocorticoid from cycle two to four.
  • Bone remodeling markers were monitored closely during treatment.
  • Furthermore, the effects of bortezomib and a glucocorticoid on immature and mature osteoblasts were also studied in vitro.
  • RESULTS: Treatment with bortezomib caused a significant increase in bone-specific alkaline phosphatase and pro-collagen type I N-terminal propeptide, a novel bone formation marker.
  • Differentiation but not proliferation was inhibited by glucocorticoid treatment.
  • CONCLUSIONS: Bortezomib used as first-line treatment significantly increased collagen deposition in patients with multiple myeloma and osteolytic lesions, but the addition of a glucocorticoid to the treatment transiently inhibited the positive effect of bortezomib, suggesting that bortezomib may result in better healing of osteolytic lesions when used without glucocorticoids in patients that have obtained remission with a previous therapy.
  • The potential bone-healing properties of single-agent bortezomib are currently being explored in a clinical study in patients who have undergone high-dose therapy and autologous stem cell transplantation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Boronic Acids / administration & dosage. Multiple Myeloma / drug therapy. Osteogenesis / drug effects. Osteolysis / drug therapy. Pyrazines / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Bortezomib. Cell Differentiation / drug effects. Cell Proliferation / drug effects. Cells, Cultured. Female. Glucocorticoids / administration & dosage. Humans. Male. Middle Aged. Osteoblasts / drug effects. Osteoblasts / pathology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • [Cites] Blood. 2000 Sep 1;96(5):1953-60 [10961900.001]
  • [Cites] Br J Haematol. 2010 Feb;148(4):551-61 [19919653.001]
  • [Cites] Haematologica. 2001 Apr;86(4):394-8 [11325645.001]
  • [Cites] Bone. 2001 May;28(5):484-90 [11344047.001]
  • [Cites] J Am Geriatr Soc. 2001 Jul;49(7):877-83 [11527478.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11581-6 [11562486.001]
  • [Cites] Rev Endocr Metab Disord. 2001 Jan;2(1):81-94 [11704982.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3527-33 [11739153.001]
  • [Cites] Tissue Eng. 2001 Dec;7(6):729-41 [11749730.001]
  • [Cites] Bone. 2002 May;30(5):685-91 [11996905.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):21-33 [12528874.001]
  • [Cites] J Clin Invest. 2003 Jun;111(11):1771-82 [12782679.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5438-45 [14500379.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] Br J Haematol. 2004 Aug;126(4):475-86 [15287939.001]
  • [Cites] Blood. 1990 Feb 1;75(3):715-20 [2297574.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):488-93 [8559201.001]
  • [Cites] Clin Biochem. 1997 Feb;30(1):35-40 [9056107.001]
  • [Cites] J Bone Miner Res. 1997 Jun;12(6):869-79 [9169344.001]
  • [Cites] Cytokine. 1997 Aug;9(8):613-23 [9245490.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):593-602 [9469347.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):350-7 [10050719.001]
  • [Cites] Hematol J. 2004;5(6):480-8 [15570289.001]
  • [Cites] Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):14-21 [15688598.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2472-83 [15933061.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):71-3 [16173965.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3160-5 [16030194.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):229-37 [16021633.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Apr;4(4):300-6 [16728940.001]
  • [Cites] Haematologica. 2006 Jul;91(7):929-34 [16818280.001]
  • [Cites] Mayo Clin Proc. 2006 Aug;81(8):1047-53 [16901028.001]
  • [Cites] Eur J Haematol. 2006 Sep;77(3):233-8 [16923110.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Br J Haematol. 2006 Dec;135(5):688-92 [17107351.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3024-30 [17138824.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Mar;7(5):346-53 [17562244.001]
  • [Cites] Blood. 2007 Jul 1;110(1):334-8 [17371942.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Oct 12;362(1):17-24 [17692823.001]
  • [Cites] Int J Hematol. 2007 Aug;86(2):180-5 [17875535.001]
  • [Cites] Br J Haematol. 2007 Nov;139(3):434-8 [17910634.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Feb 8;366(2):483-8 [18068671.001]
  • [Cites] J Clin Invest. 2008 Feb;118(2):491-504 [18219387.001]
  • [Cites] Int J Oncol. 2008 Jul;33(1):129-36 [18575758.001]
  • [Cites] Leuk Res. 2008 Nov;32(11):1661-8 [18394701.001]
  • [Cites] Eur J Haematol. 2009 Jan;82(1):31-8 [19067746.001]
  • [Cites] Am J Hematol. 2009 Jan;84(1):6-14 [18980173.001]
  • [Cites] Br J Haematol. 2009 Jan;144(2):169-75 [19036114.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4319-30 [19196662.001]
  • [Cites] Eur J Haematol. 2000 Nov;65(5):331-6 [11092464.001]
  • (PMID = 20528908.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Glucocorticoids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Other-IDs] NLM/ PMC2970902
  •  go-up   go-down


7. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR: The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood; 2010 Nov 25;116(22):4532-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
  • Monoclonal antibodies and T cells modified to express chimeric antigen receptors specific for B-cell lineage surface molecules such as CD20 exert antitumor activity in B-cell malignancies, but deplete normal B cells.
  • The receptor tyrosine kinase-like orphan receptor 1 (ROR1) was identified as a highly expressed gene in B-cell chronic lymphocytic leukemia (B-CLL), but not normal B cells, suggesting it may serve as a tumor-specific target for therapy.
  • We analyzed ROR1-expression in normal nonhematopoietic and hematopoietic cells including B-cell precursors, and in hematopoietic malignancies.
  • ROR1 has characteristics of an oncofetal gene and is expressed in undifferentiated embryonic stem cells, B-CLL and mantle cell lymphoma, but not in major adult tissues apart from low levels in adipose tissue and at an early stage of B-cell development.
  • We constructed a ROR1-specific chimeric antigen receptor that when expressed in T cells from healthy donors or CLL patients conferred specific recognition of primary B-CLL and mantle cell lymphoma, including rare drug effluxing chemotherapy resistant tumor cells that have been implicated in maintaining the malignancy, but not mature normal B cells.
  • T-cell therapies targeting ROR1 may be effective in B-CLL and other ROR1-positive tumors.
  • However, the expression of ROR1 on some normal tissues suggests the potential for toxi-city to subsets of normal cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2008 Jan;118(1):294-305 [18060041.001]
  • [Cites] Hum Gene Ther. 2007 Aug;18(8):712-25 [17685852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3047-52 [18287027.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):396-404 [18223214.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] Int J Cancer. 2008 Sep 1;123(5):1190-5 [18546292.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2427-37 [18551193.001]
  • [Cites] Leuk Lymphoma. 2008 Jul;49(7):1360-7 [18604725.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2261-71 [18509084.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4912-20 [18794548.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):605-11 [19075267.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4759-68 [19567591.001]
  • [Cites] Leukemia. 2010 Mar;24(3):563-72 [20072155.001]
  • [Cites] Semin Hematol. 2010 Apr;47(2):187-98 [20350666.001]
  • [Cites] Blood. 2010 Apr 1;115(13):2619-29 [19965642.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56 [20304086.001]
  • [Cites] Expert Rev Hematol. 2009 Oct;2(5):517-32 [21083018.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):70-5 [11753365.001]
  • [Cites] Cell Mol Life Sci. 2002 Jan;59(1):83-96 [11846036.001]
  • [Cites] J Anat. 2002 Mar;200(Pt 3):249-58 [12033729.001]
  • [Cites] Mol Ther. 2004 Apr;9(4):577-86 [15093188.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):469-79 [15314075.001]
  • [Cites] Cell. 1974 Oct;3(2):127-33 [4426090.001]
  • [Cites] J Cell Biol. 1985 Mar;100(3):965-73 [3972906.001]
  • [Cites] J Immunol Methods. 1990 Apr 17;128(2):189-201 [1691237.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):26181-90 [1334494.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Immunol Cell Biol. 1997 Oct;75(5):446-55 [9429891.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3535-42 [15304387.001]
  • [Cites] Methods Cell Biol. 2004;75:559-76 [15603442.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):591-600 [15864305.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1797-805 [15965501.001]
  • [Cites] Stem Cells. 2006 Dec;24(12):2677-84 [16916927.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):385-97 [17707828.001]
  • [CommentIn] Blood. 2010 Nov 25;116(22):4387-8 [21109622.001]
  • (PMID = 20702778.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / R01 CA136551; United States / NCI NIH HHS / CA / CA136551; United States / NCI NIH HHS / CA / CA18029
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; EC 2.7.10.1 / ROR1 protein, human; EC 2.7.10.1 / Receptor Tyrosine Kinase-like Orphan Receptors
  • [Other-IDs] NLM/ PMC2996114
  •  go-up   go-down


8. Uehara E, Tasaka T, Matsuhashi Y, Fujita M, Tamura T, Shimoura Y, Mano S, Kuwajima M, Nagai M: Peripheral T-cell lymphoma presenting with rapidly progressing myelofibrosis. Leuk Lymphoma; 2003 Feb;44(2):361-3
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma presenting with rapidly progressing myelofibrosis.
  • Myelofibrosis following peripheral T-cell lymphoma has rarely been reported.
  • Described here is a case of peripheral T-cell lymphoma with myelofibrosis and elevated transforming growth factor beta (TGF-beta).
  • His bone marrow showed fibrosis and was infiltrated with small lymphoid cells and a few residual normal hematopoietic cells.
  • Biopsy of the left inguinal lymph node revealed diffuse mature small lymphoid cells with atypical nuclei.
  • T-cell receptor beta-chain gene was rearranged in bone marrow cells.
  • He was diagnosed as having peripheral T-cell lymphoma complicated with myelofibrosis.
  • Chemotherapy was administrated which improved his pancytopenia and symptoms.
  • Two years later, anemia and thrombocytopenia developed rather quickly, he died because of progression of myelofibrosis with severe pancytopenia.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / diagnosis. Primary Myelofibrosis / etiology
  • [MeSH-minor] Aged. Anemia / etiology. Fatal Outcome. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Humans. Immunophenotyping. Male. Thrombocytopenia / etiology. Transforming Growth Factor beta / blood

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12688359.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta
  •  go-up   go-down


9. Protheroe AS, Pickard C, Johnson PW, Craddock T, Shefta J, Short K, Lancaster F, Selby PJ, Henwood J, Boylston AW: Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. Br J Haematol; 2000 Dec;111(3):766-73
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue.
  • Analysing the regeneration of T lymphocytes after high-dose chemotherapy with autologous peripheral blood progenitor cell rescue (PBPCR) may help elucidate the mechanisms of immune recovery.
  • The T-cell receptor variable beta chain (TCRBV) repertoire of adult patients undergoing high-dose chemotherapy was analysed by flow cytometry, before and after treatment.
  • We demonstrated that, in these patients, following high-dose chemotherapy and autologous stem cell transplantation, the clonal expansions reappeared in peripheral blood and returned to pretransplant levels.
  • These were shown to be predominantly clonal, with the same sequences being identified in peripheral blood before and after PBPCR, providing evidence that the overwhelming majority of T cells in these expansions arise from mature lymphocytes.
  • This study demonstrated that patients undergoing autologous PBPCR for high-dose chemotherapy regenerate clonal expansions, consistent with pretreatment levels.
  • They also regenerate T-cell repertoires with each TCRBV family represented to a similar level as that prior to high-dose chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Bone Marrow Purging. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Hematopoietic Stem Cell Transplantation. T-Lymphocytes / immunology
  • [MeSH-minor] Amino Acid Sequence. Breast Neoplasms / immunology. Breast Neoplasms / surgery. Carcinoma, Small Cell / immunology. Carcinoma, Small Cell / surgery. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Drug Administration Schedule. Female. Flow Cytometry. Fluorescent Antibody Technique, Direct. Germinoma / immunology. Germinoma / surgery. Humans. Lung Neoplasms / immunology. Lung Neoplasms / surgery. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / surgery. Male. Melanoma / immunology. Melanoma / surgery. Middle Aged. Molecular Sequence Data. Multiple Myeloma / immunology. Multiple Myeloma / surgery. Polymerase Chain Reaction / methods. Receptor-CD3 Complex, Antigen, T-Cell / genetics. Transplantation, Autologous

  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11122136.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Receptor-CD3 Complex, Antigen, T-Cell; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine
  •  go-up   go-down


10. Wei YF, Wang SY, Ren LL: [Efficacy of shenqi fuzheng injection combined with chemotherapy in treatment of acute leukemia and its effect on T-lymphocyte subsets, serum IFN-gamma, IL-10 and IL-2]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Apr;25(4):303-6
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of shenqi fuzheng injection combined with chemotherapy in treatment of acute leukemia and its effect on T-lymphocyte subsets, serum IFN-gamma, IL-10 and IL-2].
  • OBJECTIVE: To investigate the clinical efficacy of Shenqi Fuzheng Injection (SFI) combined with chemotherapy in treatment of patients with acute leukemia and its effect on the levels of T-lymphocyte subsets (CD4, CD8, CD4/CD8) and serum interferon-gamma(IFN-gamma), interleukin-10 (IL-10) and IL-2.
  • METHODS: Sixty-five patients with initial treating acute leukemia were randomly divided into 2 groups, the SFI group (n = 32) treated with SFI plus chemotherapy (CT), the control group (n = 33) treated with CT only.
  • The remission rate, changes of peripheral mature neutrophilic granulocyte (PMNG) count, T-lymphocyte subsets, serum IL-10 and IL-2 before and after treatment were determined.
  • The levels of CD4, CD4 /CD8, IFN-gamma and IL-2 all increased in the two groups after treatment (P < 0.05, P < 0.01), however, that of IL-10 was significantly decreased (P < 0.01).
  • The difference between the two groups in these criteria after treatment was also significant (P < 0.05).
  • CONCLUSION: SFI can improve and regulate the immune function of the patients with acute leukemia undergoing CT, it could promote bone marrow cells proliferation and enhance the efficacy.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892271.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; 0 / Interleukin-2; 130068-27-8 / Interleukin-10; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


11. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol; 2005 May;129(3):366-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
  • The World Health Organization (WHO) lymphoma classification recognises anaplastic large cell lymphoma (ALCL), angioimmunoblastic lymphoma (AIL) and peripheral T-cell lymphoma, unspecified (PTCU) as nodal mature T-cell lymphomas.
  • To a large extent, the IPI score explains the differences in survival between histological subtypes of nodal mature T-cell lymphomas.
  • The IPI may therefore be used for risk stratification in clinical trials to identify patients who would benefit most from new treatment strategies, such as high-dose chemotherapy followed by stem cell or bone marrow transplantation.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Severity of Illness Index
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Transplantation. Cause of Death. Epidemiologic Methods. Female. Hematopoietic Stem Cell Transplantation. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy. Male. Middle Aged. Neoplasms, Second Primary. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842660.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Dearden C: Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm; 2004 Aug;19(4):391-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab in peripheral T-cell malignancies.
  • Over the past 5 years, a number of trials have demonstrated that alemtuzumab has clinical activity in mature T-cell diseases such as T-cell prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphoma (CTCL).
  • In heavily pretreated relapsed/refractory patients alemtuzumab induced responses in more than two thirds of T-PLL and more than 50% of CTCL patients.
  • Alemtuzumab is particularly effective in clearing malignant lymphocytes from peripheral blood and bone marrow and may therefore facilitate stem-cell transplantation (SCT) in selected patients.
  • The toxicity profile for the antibody is acceptable; the major complications are infusional reactions, which generally subside after the first 1-2 weeks of therapy, and prolonged lymphopenia associated with reactivation of viruses.
  • These can be minimized by careful monitoring and the use of prophylactic therapy.
  • Future studies will be directed toward: alternative routes (subcutaneous) and schedules of administration; use as first-line therapy; combination strategies with conventional chemotherapy; and use of alemtuzumab to purge minimal residual bone-marrow disease prior to SCT.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Prolymphocytic / drug therapy. Leukemia, T-Cell / drug therapy. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Mary Ann Liebert, Inc.
  • (PMID = 15453953.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Number-of-references] 34
  •  go-up   go-down


13. Mann G, Trebo MM, Haas OA, Grümayer-Panzer ER, Dworzak MN, Lion T, Gadner H: Philadelphia chromosome-positive mature B-cell (Burkitt cell) leukaemia. Br J Haematol; 2002 Aug;118(2):559-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia chromosome-positive mature B-cell (Burkitt cell) leukaemia.
  • The bone marrow aspirate of a 9-year-old boy showed a L3 blast cell morphology in 90% of cells; immunophenotyping revealed a mature B-blast population.
  • Chemotherapy according to the Berlin-Frankfurt-Munster non-Hodgkin's lymphoma (NHL-BFM 95) protocol with maintenance according to the BFM acute lymphoblastic leukaemia (ALL-BFM 90) protocol resulted in continuing complete remission of 54 months.
  • [MeSH-major] Burkitt Lymphoma / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Child. Fusion Proteins, bcr-abl / genetics. Gene Rearrangement, B-Lymphocyte, Light Chain. Humans. Immunophenotyping / methods. Karyotyping / methods. Male. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12139745.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


14. Hoelzer D, Gökbuget N: T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma; 2009;9 Suppl 3:S214-21
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
  • T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are considered the same disease, differing by the extent of bone marrow infiltration.
  • Immunophenotypes of T-LBL and T-ALL are identical but differ in frequency, with a higher rate of cortical or mature immunophenotypes in T-LBL, which is probably related to the higher rate (> 90%) of mediastinal tumors.
  • Treatment approaches in T-LBL changed from conventional non-Hodgkin lymphoma (NHL) protocols to intensive NHL protocols but recently to ALL-designed protocols.
  • Mediastinal tumors resolve in most cases of T-ALL with chemotherapy only, whereas in T-LBL additional mediastinal irradiation seems to be beneficial.
  • Strategies for stem cell transplantation (SCT) in T-LBL and T-ALL differ.
  • Autologous SCT in complete remission (CR) in T-LBL gives a 70% survival rate, which is similar to chemotherapy alone.
  • In T-ALL, the subtypes of early and mature T-ALL have a poor outcome with chemotherapy alone (< 30%) and might profit from an allogeneic transplantation in first CR (OS > 50%).
  • MRD may guide further treatment strategies in T-ALL and probably also in T-LBL as indications for a SCT or for the evaluation of novel, particularly T-cell-specific, drugs.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Leukemic. Humans. Immunophenotyping. Male. Mediastinum / pathology. Medical Oncology / methods. Middle Aged. Prognosis. Remission Induction. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778844.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


15. Dearden CE, Matutes E, Catovsky D: Alemtuzumab in T-cell malignancies. Med Oncol; 2002;19 Suppl:S27-32
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab in T-cell malignancies.
  • We summarize the results of our experience using alemtuzumab to treat a range of clinically aggressive, mature, post-thymic, T-cell malignancies, including T-cell prolymphocytic leukemia (T-PLL), cutaneous T-cell lymphoma (CTCL), T-cell large granular lymphocyte (T-LGL) leukemia, and human T-cell lymphotropic virus I (HTLV-I) associated adult T-cell leukemia-lymphoma (ATLL).
  • Alemtuzumab was administered at a dose of 30 mg, three times a week until maximum response.
  • Apart from first-dose reactions, which were common, treatment was well tolerated, the main complication being infection and viral reactivation associated with the prolonged lymphopenia.
  • Our results indicate that alemtuzumab has activity in T-cell malignancies, particularly in T-PLL and in patients with predominantly blood and bone marrow disease.
  • It may be possible to prolong response duration by the use of high-dose therapy and stem cell transplantation.
  • Alemtuzumab may also have a role in purging minimal residual disease following other chemotherapy and prior to transplantation.
  • We conclude that treatment with alemtuzumab may offer new hope to patients who otherwise have a bleak prognosis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / drug effects. Antigens, Neoplasm / drug effects. Antineoplastic Agents / therapeutic use. Glycoproteins / drug effects. Lymphoma, T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1997 Jun;97(3):669-72 [9207420.001]
  • [Cites] Blood. 1993 Aug 1;82(3):807-12 [7687895.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Blood. 1989 May 1;73(6):1431-9 [2713487.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4491-508 [9845514.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Blood. 1998 May 15;91(10):3920-6 [9573030.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3257-63 [9779699.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):617-9 [9054672.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):432-3 [8094189.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] Oncogene. 1998 Feb 12;16(6):789-96 [9488043.001]
  • [Cites] Leuk Lymphoma. 1990;2(3-4):179-93 [27456733.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • (PMID = 12180489.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Number-of-references] 18
  •  go-up   go-down


16. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A, Berlin-Frankfurt-Münster group: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol; 2010 Jul 1;28(19):3115-21
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
  • PURPOSE: The activity of rituximab in pediatric B-cell non-Hodgkin's lymphoma (B-NHL) has not yet been determined.
  • Treatment consisted of rituximab at 375 mg/m(2) administered intravenously on day 1; concomitant therapy consisted of rasburicase, intrathecally (IT) triple drug (methotrexate, cytarabine, and prednisolone) on days 1 and 3 for CNS-positive patients and steroids only for anaphylaxis.
  • Response criterion was the product of the two largest perpendicular diameters of one to three lesions and/or the percentage of blasts in bone marrow (BM) or peripheral blood (PB) within 24 hours before rituximab and on day 5.
  • Forty-nine patients were not evaluable for response because of withdrawal from the study (n = 16), IT therapy in CNS-negative patients (n = 8), corticosteroid treatment (n = 3), technical inadequacy of response evaluation (n = 21), or no evaluable lesion (n = 1).
  • Of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%); among them, 27 of 67 with Burkitt lymphoma and seven of 15 with diffuse large B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Fatigue / chemically induced. Female. Fever / chemically induced. Humans. Infant. Infusions, Intravenous. Male. Nausea / chemically induced. Rituximab. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Jul 1;28(19):3104-6 [20516430.001]
  • (PMID = 20516455.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


17. Stamatoullas A, Buchonnet G, Lepretre S, Lenain P, Lenormand B, Duval C, Callat MP, Gaulard P, Bastard C, Tilly H: De novo acute B cell leukemia/lymphoma with t(14;18). Leukemia; 2000 Nov;14(11):1960-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo acute B cell leukemia/lymphoma with t(14;18).
  • The t(14;18)(q32;q21) translocation is the most common translocation in B cell malignancies being found in 80% of follicular lymphomas and about 20% of diffuse large B cell lymphomas.
  • Only rare cases of de novo acute B cell lymphoblastic leukemia with t(14;18) have been described.
  • None of these patients had prior history of follicular lymphoma.
  • The disease was characterized by acute clinical features with nodal and/or extranodal disease, massive bone marrow infiltration and rapid increase of circulating blast cells of mature B cell phenotype.
  • Despite intensive chemotherapy, including for two patients allogeneic bone marrow transplantation in first complete remission, all patients died within a few months.
  • De novo leukemia/lymphoma with t(14;18) is a rare entity with a very poor prognosis.
  • Whether early bone marrow transplant could modify the natural history of the disease remains to be determined.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 18 / ultrastructure. Lymphoma, B-Cell / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Blast Crisis / drug therapy. Blast Crisis / genetics. Blast Crisis / pathology. Bone Marrow / pathology. Bone Marrow Transplantation. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Disease Progression. Female. Genes, bcl-2. Genes, myc. Genes, p53. Humans. Immunophenotyping. Leukemic Infiltration. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Follicular / therapy. Male. Meninges / pathology. Middle Aged. Neoplastic Cells, Circulating. Prognosis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcl-6. Recurrence. Salvage Therapy. Transcription Factors / genetics. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11069032.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors
  •  go-up   go-down


18. Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de Thé H, El-Sabban ME, Hermine O: New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol; 2004 Nov;5(11):664-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New therapeutic approaches for adult T-cell leukaemia.
  • Adult T-cell leukaemia or lymphoma is an aggressive malignant disease of mature activated T cells caused by human T-cell lymphotropic virus type I.
  • In acute adult T-cell leukaemia, clinical trials in Japan show that although non-targeted combinations of chemotherapy improve response, they do not have a significant effect on complete remission and survival.
  • Antiretroviral therapy with combination zidovudine and interferon alfa, which induces a high rate of complete remission and lengthens survival, should be the first treatment option in acute adult T-cell leukaemia.
  • Patients with adult T-cell lymphoma might benefit from initial aggressive chemotherapy followed by antiretroviral therapy.
  • To prevent relapse in all patients allogeneic bone-marrow transplantation when feasible, or additional targeted therapy, should be mandatory.
  • Based on current pathophysiology, we discuss promising new drugs such as arsenic trioxide, proteasome inhibitors, retinoids, and angiogenesis inhibitors, as well as cellular immunotherapy.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Immunocompromised Host. Japan. Prognosis

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15522654.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antibodies, Monoclonal
  • [Number-of-references] 75
  •  go-up   go-down


19. Dearden CE, Matutes E: Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract Res Clin Haematol; 2006;19(4):795-810

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab in T-cell lymphoproliferative disorders.
  • Recently it has been demonstrated in a number of clinical trials that alemtuzumab has clinical activity in mature T-cell diseases such as T-prolymphocytic leukaemia and cutaneous T-cell lymphoma, inducing responses in up to two thirds of heavily pre-treated relapsed/refractory patients.
  • Future studies will be directed towards alternative (subcutaneous) routes and schedules of administration, use as first-line therapy, combination strategies, and role of alemtuzumab to purge minimal residual bone-marrow disease prior to stem-cell transplantation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Glycoproteins / antagonists & inhibitors. Lymphoproliferative Disorders / drug therapy. T-Lymphocytes / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997184.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Number-of-references] 67
  •  go-up   go-down


20. Romero-Guadarrama MB, Aguilar-Martínez E: Extranodal nasal NK/T-cell lymphoma with dissemination to the central nervous system: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):993-7
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal nasal NK/T-cell lymphoma with dissemination to the central nervous system: a case report.
  • BACKGROUND: Lymphomas that infiltrate the nervous system in children correspond to those of precursor B cells, such as lymphoblastic and Burkitt's lymphoma.
  • In adults, infiltration occurs in mature B-cell lymphomas, such as mantle cell lymphoma, and, rarely, in Hodgkin's lymphoma or peripheral NK/T-cell lymphomas.
  • CASE: We report the case of a 48-year-old man, who two years before death was diagnosed with extranodal nasal NK/T-cell lymphoma nasal in the left nostril.
  • He also presented infiltration to the bone marrow and underwent chemotherapy.
  • Infiltration to the central nervous system was revealed by computed axial tomography, and cytologic study of cerebrospinal fluid revealed malignant lymphoid cells; he then received intrathecal chemotherapy.
  • CONCLUSION: In Mexico, extranodal nasal NK/T-cell lymphoma occurs frequently.
  • [MeSH-major] Central Nervous System / pathology. Lymphoma, Extranodal NK-T-Cell / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Antigens, CD3 / metabolism. Bone Marrow Cells / pathology. Cell Nucleus / pathology. Cerebrospinal Fluid / cytology. Fatal Outcome. Humans. Male. Middle Aged. Nasal Cavity / pathology. Vacuoles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053585.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3
  •  go-up   go-down


21. Shimizu S, Tamagawa Y, Kojima H, Mori N, Nagata M, Noguchi M, Nagasawa T: Simultaneous development of lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma--analyses of the clonal relatedness by sequencing CDR3 in immunoglobulin heavy chain genes. Eur J Haematol; 2003 Feb;70(2):119-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous development of lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma--analyses of the clonal relatedness by sequencing CDR3 in immunoglobulin heavy chain genes.
  • A 75-yr-old male simultaneously having lymphoplasmacytic lymphoma (LPL) and diffuse large B-cell lymphoma (DLBCL) is presented.
  • Routine laboratory tests showed moderate pancytopenia, hypercalcemia (serum calcium, 15.9 mg/dL), IgM lambda-type monoclonal gammopathy (IgG, 405 mg/dL; IgA, 42 mg/dL; and IgM, 2023 mg/dL), and lambda-type Bence-Jones protein in the urine (0.8 g/d).
  • Bone marrow biopsy showed the clusters of surface lambda-positive small-sized mature-appearing lymphoplasmacytoid cells.
  • Bone survey and computed tomographic scan showed multiple osteolytic lesions and a tumor involving the third lumbar spine (L3).
  • Although the combination chemotherapy was at least partially effective, he died of bacteremia and organ failure after three courses of chemotherapy.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic / genetics. Clone Cells / pathology. Complementarity Determining Regions / genetics. Fatal Outcome. Humans. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Male. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12581194.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


22. Dearden CE, Foss FM: Peripheral T-cell lymphomas: diagnosis and management. Hematol Oncol Clin North Am; 2003 Dec;17(6):1351-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphomas: diagnosis and management.
  • Peripheral T-cell lymphomas are a diverse group of diseases with varying clinical manifestations.
  • Response to conventional chemotherapy generally is poor.
  • Treatment using purine analogs has achieved response rates between 25% and 60% in relapsed/refractory patients, with minimal toxicity.
  • Using purine analogs in combination therapy may improve response rates, albeit with an increased risk of toxicity.
  • The role of purine analogs as first line therapy in patients who have otherwise favorable prognostic factors has not been defined.
  • Monoclonal antibody therapy has emerged in the last decade as a promising approach in treating T-cell malignancies.
  • Campath-1H is an effective and well-tolerated therapy in these diseases.
  • These results in T-PLL are significantly better than those reported with other therapies; this suggests that Campath-1H should be moved to first line therapy in this aggressive disease.
  • The way in which monoclonal antibodies work indicate that they may be particularly useful in treating patients who have minimal residual disease, and, in this setting, facilitate stem cell transplantation.
  • In addition, the activity of Campath-1H to deplete T cells has been exploited in preparative regimens before allogeneic bone marrow transplantation.
  • These approaches may be worth further investigation in patients who have T-cell lymphomas.
  • None of the therapies that are available to treat the mature T-cell neoplasms seems to be curative, other than in selected patients who have favorable ALCL.
  • There is a need for larger, prospective, randomized trials to examine these novel therapies and to further explore combination regimens, which may exploit potential synergism.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Chromosome Aberrations. Chromosomes, Human / genetics. Chromosomes, Human / ultrastructure. Combined Modality Therapy. Humans. Immunophenotyping. Neoplastic Stem Cells / pathology. Prognosis. T-Lymphocyte Subsets / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14710889.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Number-of-references] 58
  •  go-up   go-down


23. Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, Pierani P, Micalizzi C, Buffardi S, Basso G, Zanesco L, Rosolen A: Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. J Clin Oncol; 2007 Nov 20;25(33):5254-61
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
  • PURPOSE: To study the prevalence of t(8;14) at diagnosis and the response kinetics to treatment of minimal residual disease (MRD) in B-cell acute lymphoblastic leukemia (B-ALL) patients and determine its impact on prognosis.
  • Bone marrow aspirate from each patient was analyzed for the presence of t(8;14)(q24;q32) by long-distance polymerase chain reaction at diagnosis, after the first chemotherapy cycle, and after subsequent cycles until negative for MRD.
  • All of them reached clinical complete remission and most (31 of 39) became MRD negative after the first chemotherapy cycle.
  • The 3-year relapse-free survival (RFS) was 38% (SE = 17%) in patients MRD positive after the first chemotherapy cycle compared with 84% (SE = 7%) in MRD-negative patients (P = .0005), whereas there was no difference in RFS for children who reached a clinical complete remission after the first chemotherapy cycle versus those who did not (RFS = 72% and SE = 9%; RFS = 79% and SE = 11%, respectively; P = .8).
  • CONCLUSION: Our study demonstrated that MRD carries a negative prognostic impact in B-ALL patients and suggests that a better risk-adapted therapy, possibly including the use of anti-CD20 monoclonal antibody, should be considered in selected patients.
  • [MeSH-major] Burkitt Lymphoma / mortality. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024872.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


24. Kircher B, Stevanovic S, Urbanek M, Mitterschiffthaler A, Rammensee HG, Grünewald K, Gastl G, Nachbaur D: Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol; 2002 Jun;117(4):935-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion.
  • A patient with chemotherapy-refractory relapse 1 year after human leucocyte antigen (HLA)-identical, unrelated stem cell transplantation (SCT) for bcr/abl-positive common acute lymphoblastic leukaemia (ALL) received a DLI from the original donor, and achieved complete cytogenetic and molecular remission concomitantly with extensive graft-versus-host disease (GvHD).
  • Seven CD8+, donor-derived, alloreactive T-cell clones were generated by stimulating post-DLI remission cells with the patient's pretransplant mature dendritic cells.
  • The minor histocompatibility antigen (mHag) recognized by these T-cell clones was identified as HA-1, a mHag associated with acute GvHD after SCT.
  • Our finding provides evidence of HA-1-associated GvL effects after DLI that paralleled the eradication of full-blown, chemotherapy-refractory ALL relapse after allogeneic SCT.
  • [MeSH-major] Graft vs Host Disease / immunology. Lymphocyte Transfusion. Minor Histocompatibility Antigens. Oligopeptides. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. T-Lymphocytes, Cytotoxic / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060133.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HA-1 antigen; 0 / Minor Histocompatibility Antigens; 0 / Oligopeptides
  •  go-up   go-down


25. Kunisaki Y, Muta T, Yamano Y, Kobayashi Y: Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion. Int J Hematol; 2003 Nov;78(4):357-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion.
  • Abnormal plasmacytoid cells were seen in both the peripheral blood (PB) and the bone marrow (BM).
  • Computed tomography scans showed extensive thickening of the gastric wall and bilateral massive PE without lymph node or pulmonary involvement.
  • The diagnosis was gastric mucosa-associated lymphoid tissue (MALT) lymphoma infiltrating to the PE, PB, and BM.
  • The cells seemed to be divided into two populations according to their surface markers: mature B-cells (CD19+CD20+CD22+CD21+CD38-) and secretory B-cells (CD19+CD20(dim)CD22-CD21-CD38+).
  • The patient had a good response to fludarabine treatment, which was followed with rituximab therapy.
  • In general, gastric MALT lymphoma cells have a tendency to differentiate into plasma cells.
  • In this article, we show that the cell character of API-2/MLT-positive MALT lymphoma is preserved even when the cells are disseminated.
  • This is the first published case, to our knowledge, in which two differentiation stages of MALT lymphoma cells infiltrating into PE have been confirmed by flow cytometric analysis.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Oncogene Proteins, Fusion / analysis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Aged. Antigens, Differentiation, B-Lymphocyte / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. B-Lymphocytes / pathology. Cell Adhesion Molecules / analysis. Cell Differentiation. Cell Division. Humans. Immunophenotyping. Male. Neoplasm, Residual. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3944-8 [9307277.001]
  • [Cites] Blood. 2002 Jan 1;99(1):3-9 [11756145.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2019-27 [10595932.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):798-805 [11504840.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):385-93 [12512832.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] Rinsho Ketsueki. 2000 Nov;41(11):1183-8 [11193437.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):588-94 [11736940.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40 [11842387.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):683-90 [11710684.001]
  • [Cites] Gut. 2001 Oct;49(4):519-25 [11559649.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1583-93 [9137085.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):301-9 [10760689.001]
  • [Cites] Leuk Res. 1990;14(7):617-22 [2388473.001]
  • [Cites] Acta Otolaryngol Suppl. 1996;523:259-62 [9082801.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):113-7 [10704680.001]
  • [Cites] Cell. 1993 Jul 16;74(1):185-95 [7687523.001]
  • (PMID = 14686495.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Cell Adhesion Molecules; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


26. Pospísilová D, Borovicková J, Rozková D, Stary J, Seifertová D, Tobiásová Z, Spísek R, Bartunková J: Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children. Med Oncol; 2005;22(1):79-88
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children.
  • Cell immunotherapy through dendritic cells (DC) presents a hopeful strategy for the treatment of various tumors.
  • The aim of our study was to find which progenitor cells are most suitable for the preparation of dendritic cells in acute lymphoblastic leukemia (ALL) in pediatric patients, whether blasts from bone marrow or dendritic cells generated from peripheral blood mononuclear cells taken at the time of remission after induction chemotherapy.
  • DC generated from the BM blasts of patients with B-ALL and T-ALL (n = 15) at the time of diagnosis expressed low levels of costimulatory molecules and CD markers typical for mature DC.
  • When comparing both cell sources for the preparation of DC in patients with ALL, it appears that peripheral mononuclear cells obtained after chemotherapy are more suitable than bone marrow leukemic blasts due to similar morphology, phenotypic, and functional capacity to monocytes of healthy donors.
  • [MeSH-major] Dendritic Cells / immunology. Immunotherapy / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Cell Survival. Child. Child, Preschool. Female. Humans. Infant. Lymphocyte Activation. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3531-40 [10552964.001]
  • [Cites] J Immunother. 2000 Jul-Aug;23(4):487-98 [10916759.001]
  • [Cites] Br J Haematol. 1993 Mar;83(3):412-8 [8485046.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):831-44 [11843817.001]
  • [Cites] J Exp Med. 1996 Jan 1;183(1):283-7 [8551233.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1133-42 [9028934.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):1057-63 [10425303.001]
  • [Cites] J Immunol. 2000 Mar 1;164(5):2487-95 [10679086.001]
  • [Cites] J Urol. 1999 Mar;161(3):777-82 [10022683.001]
  • [Cites] Int Immunol. 2002 Jul;14(7):741-50 [12096033.001]
  • [Cites] Blood. 2001 May 1;97(9):2764-71 [11313269.001]
  • [Cites] Nat Med. 1996 Jan;2(1):52-8 [8564842.001]
  • [Cites] Cancer Immunol Immunother. 2001 Oct;50(8):417-27 [11726136.001]
  • [Cites] Crit Rev Immunol. 1998;18(1-2):65-75 [9419449.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2861-8 [12019165.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2048-55 [10477734.001]
  • [Cites] Prostate. 1999 Apr 1;39(1):54-9 [10221267.001]
  • [Cites] Leukemia. 2001 Feb;15(2):278-9 [11236945.001]
  • [Cites] Blood. 1999 Feb 1;93(3):780-6 [9920826.001]
  • [Cites] Eur J Haematol. 2003 May;70(5):333-45 [12694173.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Cancer Immunol Immunother. 2002 Apr;51(2):72-8 [11904731.001]
  • [Cites] Leuk Res. 2002 Feb;26(2):191-201 [11755469.001]
  • [Cites] Expert Opin Biol Ther. 2002 Jan;2(1):35-43 [11772338.001]
  • [Cites] Adv Cancer Res. 1992;59:245-322 [1519491.001]
  • [Cites] J Exp Med. 1988 Oct 1;168(4):1247-53 [2971756.001]
  • [Cites] Nat Med. 1998 Mar;4(3):328-32 [9500607.001]
  • [Cites] Exp Hematol. 1995 Oct;23(11):1148-51 [7556522.001]
  • (PMID = 15750200.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Nizze H, Prall F, Wigger M, Eggers G, Knieling K, Parwaresch R: [Primary renal manifestation in malignant lymphomas and leukemia]. Pathologe; 2003 Oct;24(6):460-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary manifestation of malignant lymphoma and/or leukaemia rarely occurs in the kidney.
  • At nephrectomy, a conventional (clear cell) renal cell carcinoma was found simultaneously with an occult mantle cell lymphoma infiltrating the adjacent renal and extrarenal tissue.
  • Clinical follow-up uncovered nodal and bone marrow involvement, so that a primary renal manifestation of mantle cell lymphoma was apparent.2.A 69-year-old man with suspected vertebral metastasis underwent partial renal resection because of a mass in his left kidney.
  • Histologically and immunohistochemically, the renal infiltration was diagnosed as a precursor B-lymphoblastic lymphoma.
  • After chemotherapy and irradiation, leukaemic blood cell counts with 50% lymphoblasts proved a primary renal manifestation of precursor B-lymphoblastic leukaemia/lymphoma.3.A 13-year-old boy presented clinically with renal failure, enlarged kidneys, and normal urinalysis.
  • Renal biopsy showed a diffuse interstitial infiltration with atypical T-lymphoblasts compressing tubules and surrounding preserved glomeruli.
  • Subsequent clinical bone marrow smears presented 60% T-lymphoblasts, so that the final diagnosis of a primary renal manifestation of acute T-lymphoblastic leukaemia of mature thymic cortex type was made.
  • Immediate chemotherapy resulted in total recovery of renal function and bone marrow findings.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Kidney Neoplasms / pathology. Leukemia / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Aged. Burkitt Lymphoma / pathology. Humans. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma / pathology. Lymphoma / surgery. Lymphoma, B-Cell / pathology. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1991 Dec;96(6):738-45 [1746490.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):429-31 [12540447.001]
  • [Cites] Am J Surg Pathol. 1987 May;11(5):375-82 [3555131.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Urol. 1966 Apr;95(4):485-8 [5326510.001]
  • [Cites] Ann Pathol. 2002 Jun;22(3):222-5 [12410107.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):386-91 [3594375.001]
  • [Cites] Gen Diagn Pathol. 1998 Apr;143(5-6):317-20 [9653914.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1986 Spring;8(1):8-12 [3487255.001]
  • [Cites] J Urol. 1983 Feb;129(2):364-7 [6572731.001]
  • [Cites] Pediatr Med Chir. 1982 Jan-Apr;4(1-2):107-13 [6955776.001]
  • [Cites] Arch Ital Urol Androl. 2002 Mar;74(1):44-7 [12053451.001]
  • (PMID = 14605852.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Legitimo A, Consolini R, Bencivelli W, Crimaldi G, Migliaccio P, Mosca F: Assessment of 8-methoxypsoralen and ultraviolet a light effects on human stroma generation and function. Acta Haematol; 2006;116(3):192-7
Hazardous Substances Data Bank. 8-METHOXYPSORALEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photopheresis or extracorporeal photochemotherapy (ECP) is a new immunomodulatory therapy in which a patient's leukocytes are exposed extracorporeally to 8-methoxypsoralen (8-MOP) and ultraviolet A (UVA) light.
  • Although it is used for the treatment of cutaneous T cell lymphoma, graft-versus-host disease, and several autoimmune diseases, with efficacy and safety reported in almost all studies, the mechanisms by which ECP exerts its beneficial effects are still unclear.
  • As cellular targets of this procedure are numerous, we investigated the effects of 8-MOP and UVA light on stromal precursors and mature stromal layers.
  • Human bone marrow stromal cell layers were established in long-term bone marrow culture medium from normal marrow mononuclear cells.
  • Normal marrow mononuclear cells were incubated with 8-MOP and/or exposed to UVA light (PUVA treatment) before culturing.
  • To determine whether PUVA treatment affected stromal regulation of adherent hematopoietic cell survival, mature stromal layers, incubated with 8-MOP and exposed to UVA light, were cocultured with nonadherent mononuclear cells from normal marrow.
  • After 24 h, the percentage of apoptotic hematopoietic cell precursors was quantified by flow cytometry.
  • This study provides evidences that the in vitro exposure of human stromal cell precursors to UVA light, in the presence of 8-MOP, inhibits stromal layer generation by inducing apoptosis, as evidenced by annexin V staining following 7 days of culture.
  • Here, we show an additional cell target for this psoralen following UVA irradiation.
  • However, in a second set of experiments, PUVA treatment did not affect the stromal capacity to support hematopoiesis in culture.
  • Our results can contribute to a better definition of ECP mechanisms of action for future development of experimental designs and clinical applications of this intriguing procedure.
  • [MeSH-major] Methoxsalen / pharmacology. Photopheresis / methods. Stromal Cells / drug effects. Stromal Cells / radiation effects. Ultraviolet Rays
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / radiation effects. Bone Marrow Cells / cytology. Bone Marrow Cells / drug effects. Bone Marrow Cells / radiation effects. Humans. Mesenchymal Stromal Cells / drug effects. Mesenchymal Stromal Cells / radiation effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17016038.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] U4VJ29L7BQ / Methoxsalen
  •  go-up   go-down


29. Ito C, Tecchio C, Coustan-Smith E, Suzuki T, Behm FG, Raimondi SC, Pui CH, Campana D: The antifungal antibiotic clotrimazole alters calcium homeostasis of leukemic lymphoblasts and induces apoptosis. Leukemia; 2002 Jul;16(7):1344-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with 10 microM clotrimazole (a concentration achievable in vivo) reduced cell recovery from cultures of all nine ALL cell lines studied (B-lineage: OP-1, SUP-B15, RS4;11, NALM6, REH, and 380; T-lineage: MOLT4, CCRF-CEM, and CEM-C7).
  • After 4 days of culture, median cell recovery was 10% (range, <1% to 37%) of cell recovery in parallel untreated cultures.
  • After leukemic cells from 16 cases of ALL were cultured for 7 days with 10 microM clotrimazole, median cell recovery was <1% (range, <1% to 16%) of that in parallel untreated cultures.
  • Clotrimazole was active against leukemic cells with genetic abnormalities associated with poor response to therapy and against multidrug-resistant cell lines.
  • In contrast, mature T lymphocytes and bone marrow stromal cells were not affected.
  • [MeSH-major] Antifungal Agents / pharmacology. Apoptosis / drug effects. Calcium / metabolism. Clotrimazole / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Annexin A5 / metabolism. Child. Child, Preschool. DNA Fragmentation / drug effects. Humans. Infant. Lymphocytes / drug effects. Lymphocytes / metabolism. Lymphocytes / pathology. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CLOTRIMAZOLE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12094259.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA21765; United States / NCI NIH HHS / CA / R01-CA58297
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antifungal Agents; G07GZ97H65 / Clotrimazole; SY7Q814VUP / Calcium
  •  go-up   go-down


30. Hoelzer D, Gökbuget N: Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol; 2000 Oct;36(1):49-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More recently there was no further improvement of overall results in larger prospective trials but significant advances for distinct biological subgroups of ALL such as mature B-ALL and T-ALL.
  • The paper will give a brief review on the results of chemotherapy, indications and results of bone marrow transplantation and CNS prophylaxis in adult ALL.
  • Subtype adjusted therapy, rational treatment decisions based on MRD and new, 'causative' treatment approaches are highlighted as the most promising perspectives for future improvement of treatment results in adult ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Bone Marrow Transplantation. Humans. Immunophenotyping. Neoplasm, Residual / diagnosis. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10996522.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] IRELAND
  • [Number-of-references] 53
  •  go-up   go-down


31. Rasmussen T: The presence of circulating clonal CD19+ cells in multiple myeloma. Leuk Lymphoma; 2001 Nov-Dec;42(6):1359-66
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma (MM) is a B-cell malignancy characterized by the expansion of mature plasma cells (PC) localized in the bone marrow (BM).
  • Circulating clonotypic cells respond well to induction therapy, although a small subset within the CD19 compartment is resistant even to high-dose chemotherapy.
  • Translocations involving the immunoglobulin locus (14q32) are an early non-transforming event common to both monoclonal gammopathy of undetermined significance (MGUS) and MM introduced at the memory B-cell level.
  • [MeSH-minor] Antigens, CD34 / analysis. Cell Differentiation. Clone Cells / physiology. Humans. Immunologic Memory / physiology. Plasma Cells / physiology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911420.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34
  • [Number-of-references] 66
  •  go-up   go-down


32. Marleau AM, Lipton JH, Riordan NH, Ichim TE: Therapeutic use of Aldara in chronic myeloid leukemia. J Transl Med; 2007;5:4
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic use of Aldara in chronic myeloid leukemia.
  • 2) CML-antigen reactive T cell clones exist in the patient but in many situations are ineffectively stimulated to cause significant hematological responses; and 3) Antigen presentation by mature, activated DC, which endogenously express CML-antigens may endow the pre-existing ineffective T cell responses with ability to control CML progression.
  • The practical use of Aldara as a localized activator of DC in the context of present day leukemic therapeutics, as well as various properties of this unique immune modulator will be discussed.
  • [MeSH-major] Aminoquinolines / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Adaptive Immunity / drug effects. Adaptive Immunity / immunology. Adjuvants, Immunologic / pharmacology. Adjuvants, Immunologic / therapeutic use. Humans. Immunity, Innate / drug effects. Immunity, Innate / immunology

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2003 Dec 9;108(23):2905-10 [14656915.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1037-42 [14504104.001]
  • [Cites] Novartis Found Symp. 2004;256:149-52; discussion 152-7, 259-69 [15027488.001]
  • [Cites] Int Immunol. 2004 Jun;16(6):877-87 [15113774.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):3051-61 [15322165.001]
  • [Cites] J Dermatol. 2004 Aug;31(8):627-31 [15492435.001]
  • [Cites] Best Pract Res Clin Haematol. 2004 Sep;17(3):439-51 [15498715.001]
  • [Cites] Nouv Presse Med. 1975 May 3;4(18):1337-42 [1098015.001]
  • [Cites] Blood. 1975 Dec;46(6):845-54 [1060471.001]
  • [Cites] Br J Cancer. 1977 Mar;35(3):265-72 [322689.001]
  • [Cites] J Immunol. 1982 Jan;128(1):211-6 [7033373.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;105(1):83-93 [6403549.001]
  • [Cites] Arch Intern Med. 1983 Sep;143(9):1726-31 [6577818.001]
  • [Cites] Oncology. 1985;42(5):275-81 [3897932.001]
  • [Cites] Nature. 1986 Feb 20-26;319(6055):675-8 [3951539.001]
  • [Cites] Jpn J Cancer Res. 1989 Jan;80(1):59-64 [2496059.001]
  • [Cites] J Clin Invest. 1991 Jul;88(1):67-75 [1676038.001]
  • [Cites] Nat Immun Cell Growth Regul. 1991;10(2):57-70 [1881400.001]
  • [Cites] Exp Hematol. 1991 Aug;19(7):659-63 [1909968.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1468-72 [1346932.001]
  • [Cites] Leuk Res. 1992 Jun-Jul;16(6-7):721-2 [1635387.001]
  • [Cites] Blood. 1992 Aug 1;80(3):670-7 [1379086.001]
  • [Cites] Nat Immun. 1992 May-Jun;11(3):117-32 [1392400.001]
  • [Cites] Cancer Immunol Immunother. 1992;35(6):401-11 [1394343.001]
  • [Cites] J Immunother. 1999 Mar;22(2):175-81 [10093042.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3863-5 [10339494.001]
  • [Cites] Nat Med. 1999 Jun;5(6):677-85 [10371507.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7115-9 [15585830.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):657-62 [15721470.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2476-80 [15728450.001]
  • [Cites] J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):246-51 [15739279.001]
  • [Cites] Clin Lab Sci. 2005 Winter;18(1):49-56 [15747786.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1659-69 [15747376.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jun;159(2):164-7 [15899391.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):8210-8 [15944330.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5009-14 [15958541.001]
  • [Cites] Science. 2005 Aug 26;309(5739):1380-4 [16123302.001]
  • [Cites] Hepatology. 2005 Sep;42(3):724-31 [16116638.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Oct 7;335(4):1293-304 [16112646.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):583-8 [16129707.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1788-93 [16094420.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4460-8 [15958631.001]
  • [Cites] Exp Hematol. 2005 Jul;33(7):767-75 [15963852.001]
  • [Cites] Curr Top Microbiol Immunol. 2005;293:287-302 [15981485.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9253-7 [15961541.001]
  • [Cites] Dermatol Surg. 2005 Jun;31(6):659-64 [15996416.001]
  • [Cites] Leuk Lymphoma. 2005 Jun;46(6):935-9 [16019542.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6409-17 [16024645.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5273-80 [16033846.001]
  • [Cites] J Immunol. 2005 Aug 1;175(3):1983-90 [16034143.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1143-53 [16077073.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Jul;36(4):559-61 [16078588.001]
  • [Cites] Nature. 2005 Aug 25;436(7054):1186-90 [15995699.001]
  • [Cites] Cancer Immunol Immunother. 2005 Nov;54(11):1072-81 [15959774.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3666-72 [16046526.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Dec 1;172(11):1434-9 [16151041.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):1005-16 [16283570.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):72-8 [16403097.001]
  • [Cites] Exp Dermatol. 2006 May;15(5):331-41 [16630072.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):258-65 [17034468.001]
  • [Cites] Bone Marrow Transplant. 1999 Nov;24(10):1057-63 [10578155.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1781-7 [10688838.001]
  • [Cites] Leukemia. 2000 May;14(5):859-62 [10803518.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1671-7 [10815885.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1931-5 [10815918.001]
  • [Cites] Cell Immunol. 2000 Jul 10;203(1):55-65 [10915562.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1018-23 [10973322.001]
  • [Cites] Eur Cytokine Netw. 2000 Sep;11(3):372-8 [11022120.001]
  • [Cites] Vaccine. 2001 Feb 8;19(13-14):1820-6 [11166907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7492-7 [11416219.001]
  • [Cites] J Clin Invest. 2001 Sep;108(6):895-903 [11560959.001]
  • [Cites] Med Pregl. 2001 Mar-Apr;54(3-4):128-34 [11759203.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1928-37 [11877262.001]
  • [Cites] Blood. 2002 May 15;99(10):3530-9 [11986204.001]
  • [Cites] Blood Cells Mol Dis. 2002 Jan-Feb;28(1):75-85 [11987244.001]
  • [Cites] Nat Immunol. 2002 Jun;3(6):499 [12032557.001]
  • [Cites] J Exp Med. 1993 Aug 1;178(2):597-604 [8340759.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5176-80 [8221654.001]
  • [Cites] Stem Cells. 1993 Oct;11 Suppl 3:104-8 [8298471.001]
  • [Cites] Life Sci. 1994;55(23):1767-80 [7968257.001]
  • [Cites] Bone Marrow Transplant. 1994 Sep;14(3):389-96 [7994260.001]
  • [Cites] Int Immunol. 1994 Oct;6(10):1605-12 [7826950.001]
  • [Cites] Blood. 1995 May 15;85(10):2680-4 [7742526.001]
  • [Cites] Leukemia. 1995 Jun;9(6):999-1005 [7596192.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4337-43 [7492795.001]
  • [Cites] Leuk Lymphoma. 1995 Aug;18(5-6):471-8 [8528055.001]
  • [Cites] Blood. 1996 May 1;87(9):3587-92 [8611681.001]
  • [Cites] Leukemia. 1996 Mar;10(3):483-7 [8642866.001]
  • [Cites] Blood. 1996 Nov 1;88(9):3522-7 [8896419.001]
  • [Cites] Br J Cancer. 1996 Nov;74(9):1482-6 [8912549.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1133-42 [9028934.001]
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):301-13 [9684928.001]
  • [Cites] J Infect Dis. 1998 Sep;178(3):858-61 [9728559.001]
  • [Cites] Blood. 1999 Jan 1;93(1):284-92 [9864172.001]
  • [Cites] J Exp Med. 2002 Aug 5;196(3):389-99 [12163567.001]
  • [Cites] Cell Immunol. 2002 Jul-Aug;218(1-2):74-86 [12470615.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1033-6 [12532024.001]
  • [Cites] J Clin Invest. 2003 Mar;111(5):639-47 [12618518.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1010-2 [12764362.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):691-6 [12847235.001]
  • [Cites] Cytotherapy. 2003;5(3):259-72 [12850795.001]
  • [Cites] Carcinogenesis. 2003 Oct;24(10):1571-80 [12919958.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4320-8 [14530357.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):6275-82 [14634145.001]
  • (PMID = 17254347.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  • [Number-of-references] 108
  • [Other-IDs] NLM/ PMC1790884
  • [General-notes] NLM/ Original DateCompleted: 20070802
  •  go-up   go-down


33. Gökbuget N, Hoelzer D, Arnold R, Böhme A, Bartram CR, Freund M, Ganser A, Kneba M, Langer W, Lipp T, Ludwig WD, Maschmeyer G, Rieder H, Thiel E, Weiss A, Messerer D: Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am; 2000 Dec;14(6):1307-25, ix
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).
  • This article provides an overview on aims, treatment concepts, and results of these studies.
  • It includes brief summaries on the development of prognostic models within the GMALL group and on approaches for prophylaxis of CNS relapse, and it summarizes specific treatment concepts for mature B-lineage acute lymphocytic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Transplantation. Central Nervous System Neoplasms / prevention & control. Clinical Trials as Topic. Combined Modality Therapy. Cranial Irradiation. Germany / epidemiology. Humans. Immunophenotyping. Injections, Spinal. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Methotrexate / administration & dosage. Middle Aged. Models, Theoretical. Multicenter Studies as Topic. Pilot Projects. Prognosis. Prospective Studies. Randomized Controlled Trials as Topic. Remission Induction. Risk. Survival Rate. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11147225.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 39
  •  go-up   go-down






Advertisement